HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pasternak, G. W. Search for Related Content PubMed PubMed Citation Articles by Pasternak, G. W.

Opiate, enkephalin, and endorphin analgesia

Relations to a single subpopulation of opiate receptors

George C. Cotzias Laboratory of Neuro-Oncology, Memorial Slosn-Kettering Cancer Center, and the Departments of Neurology and Pharmacology. Cornell University Medical College. New York. NY.

Differences in the receptor mechanisms of opiate analgesia and respiratory depression have been studied with three novel irreversible opiates. A single injection of the irreversible agonist oxymorphazone produces analgesia in mice, lasting over 24 hours. Conversely, the irreversible antagonist naloxazone dramatically reduces the analgesic effectiveness of a variety of opiate alkaloids and enkephalin analogs for over a day. Despite this marked reduction in analgesia after naloxazone treatment, morphine lethality (LD₅₀) is unchanged in similarly treated mice. Receptor binding studies show that naloxazone irreversibly and selectively blocks a subpopulation of opiate receptors (the mu₁ sites) to which all classes of opiates and e-nkephalins bind with highest affinity, whereas the drug has little to no effect on their lower-affinity sites (mu₂ and delta). The return of high-affinity receptor (mu₁) binding to normal levels corresponds closely to the return of analgesic sensitivity and possibly represents receptor turnover in the central nervous system. These studies suggest that both opiate and opioid peptide analgesia is mediated through a single receptor subpopulation distinct from those involved with respiratory depression, and raise the possibility of specific opiate analgesics without respiratory depression.

Address correspondence and reprint requests to Dr. Pasternak. Department of Neurology. Memorial Sloan-Kettering Cancer Center. 1275 York Avenue, New York. NY 10021

Accepted for publication February 5. 1981

This work was supported in part by grants from NIDA (No. DA 02615) and the American Cancer Society i No. PDT-l69). Dr. Pasternak is the recipient of a Teacher-Investigator Award from the NINCIE (No NS-00415).

This article has been cited by other articles:

				G. Ling, J. MacLeod, S Lee, S. Lockhart, and G. Pasternak Separation of morphine analgesia from physical dependence Science, October 26, 1984; 226(4673): 462 - 464. [Abstract] [PDF]